Tacrolimus (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Tacrolimus" in English language version.

refsWebsite

Global rank English rank

44nih.gov

4^th place

34doi.org

2^nd place

12semanticscholar.org

11^th place

8^th place

6web.archive.org

1^st place

5europa.eu

68^th place

117^th place

3fda.gov

447^th place

338^th place

2drugs.com

399^th place

333^rd place

2clincalc.com

3,912^th place

2,496^th place

1canada.ca

1,712^th place

1,063^rd place

1wedgewoodpetrx.com

low place

1handle.net

102^nd place

76^th place

1medscape.com

719^th place

636^th place

1mspca.org

low place

1clinicaltrials.gov

5,225^th place

4,062^nd place

1cancer.org

3,680^th place

2,918^th place

1bad.org.uk

low place

1thelancet.com

2,393^rd place

3,174^th place

1who.int

195^th place

302^nd place

1ucl.ac.uk

1,306^th place

885^th place

1medicinescomplete.com

low place

bad.org.uk

Cox NH, Smith CH (December 2002). "Advice to dermatologists re topical tacrolimus" (PDF). Therapy Guidelines Committee. British Association of Dermatologists. Archived from the original (PDF) on 13 December 2013.

canada.ca

"Drug and medical device highlights 2019: Helping you maintain and improve your health". Health Canada. 18 November 2020. Retrieved 28 March 2024.

cancer.org

"Key Statistics for Non-Hodgkin Lymphoma". www.cancer.org. Retrieved 19 February 2020.

clincalc.com

"The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
"Tacrolimus - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.

clinicaltrials.gov

Naves FE, Sakassegawa E (10 May 2013). "Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops". U.S. National Library of Medicine. Retrieved 5 August 2022.

doi.org

Berdoulay A, English RV, Nadelstein B (2005). "Effect of topical 0.02% tacrolimus aqueous suspension on tear production in dogs with keratoconjunctivitis sicca". Veterinary Ophthalmology. 8 (4): 225–232. doi:10.1111/j.1463-5224.2005.00390.x. PMID 16008701.
Baldo A, Cafiero M, Di Caterino P, Di Costanzo L (January 2009). "Tacrolimus ointment in the management of atopic dermatitis". Clinical, Cosmetic and Investigational Dermatology. 2: 1–7. doi:10.2147/ccid.s3378. PMC 3047924. PMID 21436963.
Haddad EM, McAlister VC, Renouf E, Malthaner R, Kjaer MS, Gluud LL (October 2006). McAlister V (ed.). "Cyclosporin versus tacrolimus for liver transplanted patients". The Cochrane Database of Systematic Reviews. 2006 (4): CD005161. doi:10.1002/14651858.CD005161.pub2. PMC 8865611. PMID 17054241.
O'Grady JG, Burroughs A, Hardy P, Elbourne D, Truesdale A (October 2002). "Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial". Lancet. 360 (9340): 1119–1125. doi:10.1016/S0140-6736(02)11196-2. PMID 12387959. S2CID 10417106.
Lee MN, Butani L (June 2007). "Improved pharmacokinetic monitoring of tacrolimus exposure after pediatric renal transplantation". Pediatric Transplantation. 11 (4): 388–393. doi:10.1111/j.1399-3046.2006.00618.x. PMID 17493218. S2CID 23530214.
Cury Martins J, Martins C, Aoki V, Gois AF, Ishii HA, da Silva EM (July 2015). "Topical tacrolimus for atopic dermatitis". The Cochrane Database of Systematic Reviews. 2015 (7): CD009864. doi:10.1002/14651858.CD009864.pub2. PMC 6461158. PMID 26132597.
Devasenapathy N, Chu A, Wong M, Srivastava A, Ceccacci R, Lin C, et al. (January 2023). "Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis". The Lancet. Child & Adolescent Health. 7 (1): 13–25. doi:10.1016/S2352-4642(22)00283-8. PMID 36370744. S2CID 253470127.
Silverberg NB, Lin P, Travis L, Farley-Li J, Mancini AJ, Wagner AM, et al. (November 2004). "Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases". Journal of the American Academy of Dermatology. 51 (5): 760–766. doi:10.1016/j.jaad.2004.05.036. PMID 15523355.
Yazu H, Fukagawa K, Shimizu E, Sato Y, Fujishima H (February 2021). "Long-term outcomes of 0.1% tacrolimus eye drops in eyes with severe allergic conjunctival diseases". Allergy, Asthma, and Clinical Immunology. 17 (1): 11. doi:10.1186/s13223-021-00513-w. PMC 7852099. PMID 33522964.
Fukatsu S, Fukudo M, Masuda S, Yano I, Katsura T, Ogura Y, et al. (April 2006). "Delayed effect of grapefruit juice on pharmacokinetics and pharmacodynamics of tacrolimus in a living-donor liver transplant recipient". Drug Metabolism and Pharmacokinetics. 21 (2): 122–125. doi:10.2133/dmpk.21.122. PMID 16702731.
Naesens M, Kuypers DR, Sarwal M (February 2009). "Calcineurin inhibitor nephrotoxicity". Clinical Journal of the American Society of Nephrology. 4 (2): 481–508. doi:10.2215/CJN.04800908. PMID 19218475.
Miwa Y, Isozaki T, Wakabayashi K, Odai T, Matsunawa M, Yajima N, et al. (2008). "Tacrolimus-induced lung injury in a rheumatoid arthritis patient with interstitial pneumonitis". Modern Rheumatology. 18 (2): 208–211. doi:10.1007/s10165-008-0034-3. PMID 18306979. S2CID 39537409.
O'Donnell MM, Williams JP, Weinrieb R, Denysenko L (2007). "Catatonic mutism after liver transplant rapidly reversed with lorazepam". General Hospital Psychiatry. 29 (3): 280–281. doi:10.1016/j.genhosppsych.2007.01.004. PMID 17484951.
Hanifin JM, Paller AS, Eichenfield L, Clark RA, Korman N, Weinstein G, et al. (August 2005). "Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis". Journal of the American Academy of Dermatology. 53 (2 Suppl 2): S186 – S194. doi:10.1016/j.jaad.2005.04.062. PMID 16021174.
Devasenapathy N, Chu A, Wong M, Srivastava A, Ceccacci R, Lin C, et al. (January 2023). "Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis". The Lancet. Child & Adolescent Health. 7 (1): 13–25. doi:10.1016/S2352-4642(22)00283-8. PMID 36370744. S2CID 253470127.
Cogliano VJ, Corsini E, Fournier A, Nelson HH, Sergi CM, Antunes AMM, et al. (29 November 2024). "Carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus". The Lancet Oncology. 26 (1): 15–16. doi:10.1016/S1470-2045(24)00685-5. PMID 39622256.{{cite journal}}: CS1 maint: multiple names: authors list (link)
Liu J, Farmer JD, Lane WS, Friedman J, Weissman I, Schreiber SL (August 1991). "Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes". Cell. 66 (4): 807–815. doi:10.1016/0092-8674(91)90124-H. PMID 1715244. S2CID 22094672.
Abou-Jaoude MM, Najm R, Shaheen J, Nawfal N, Abboud S, Alhabash M, et al. (September 2005). "Tacrolimus (FK506) versus cyclosporine microemulsion (neoral) as maintenance immunosuppression therapy in kidney transplant recipients". Transplantation Proceedings. 37 (7): 3025–3028. doi:10.1016/j.transproceed.2005.08.040. PMID 16213293.
Staatz CE, Tett SE (2004). "Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation". Clinical Pharmacokinetics. 43 (10): 623–653. doi:10.2165/00003088-200443100-00001. PMID 15244495. S2CID 33877550.
Staatz CE, Goodman LK, Tett SE (March 2010). "Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I". Clinical Pharmacokinetics. 49 (3): 141–175. doi:10.2165/11317350-000000000-00000. PMID 20170205. S2CID 28346861.
Staatz CE, Goodman LK, Tett SE (April 2010). "Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II". Clinical Pharmacokinetics. 49 (4): 207–221. doi:10.2165/11317550-000000000-00000. PMID 20214406. S2CID 27047235.
Barbarino JM, Staatz CE, Venkataramanan R, Klein TE, Altman RB (October 2013). "PharmGKB summary: cyclosporine and tacrolimus pathways". Pharmacogenetics and Genomics. 23 (10): 563–585. doi:10.1097/fpc.0b013e328364db84. PMC 4119065. PMID 23922006.
Benkali K, Prémaud A, Picard N, Rérolle JP, Toupance O, Hoizey G, et al. (1 January 2009). "Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients". Clinical Pharmacokinetics. 48 (12): 805–816. doi:10.2165/11318080-000000000-00000. PMID 19902988. S2CID 19900291.
Choi Y, Jiang F, An H, Park HJ, Choi JH, Lee H (January 2017). "A pharmacogenomic study on the pharmacokinetics of tacrolimus in healthy subjects using the DMETTM Plus platform". The Pharmacogenomics Journal. 17 (1): 105–106. doi:10.1038/tpj.2016.85. PMID 27958377.
Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M, et al. (September 1987). "FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics". The Journal of Antibiotics. 40 (9): 1249–1255. doi:10.7164/antibiotics.40.1249. PMID 2445721.
Pritchard DI (May 2005). "Sourcing a chemical succession for cyclosporin from parasites and human pathogens". Drug Discovery Today. 10 (10): 688–691. doi:10.1016/S1359-6446(05)03395-7. PMID 15896681. Supports source organism, but not team information
Starzl TE (1992). "Chapter 25: The drug with no name". The Puzzle People: Memoirs Of A Transplant Surgeon. University of Pittsburgh Press. pp. 288–308. doi:10.2307/j.ctt9qh63b. ISBN 978-0-8229-3714-2.
Ordóñez-Robles M, Santos-Beneit F, Martín JF (May 2018). "Unraveling Nutritional Regulation of Tacrolimus Biosynthesis in Streptomyces tsukubaensis through omic Approaches". Antibiotics. 7 (2): 39. doi:10.3390/antibiotics7020039. PMC 6022917. PMID 29724001.
Chen D, Zhang L, Pang B, Chen J, Xu Z, Abe I, et al. (May 2013). "FK506 maturation involves a cytochrome p450 protein-catalyzed four-electron C-9 oxidation in parallel with a C-31 O-methylation". Journal of Bacteriology. 195 (9): 1931–1939. doi:10.1128/JB.00033-13. PMC 3624582. PMID 23435975.
Mo S, Ban YH, Park JW, Yoo YJ, Yoon YJ (December 2009). "Enhanced FK506 production in Streptomyces clavuligerus CKD1119 by engineering the supply of methylmalonyl-CoA precursor". Journal of Industrial Microbiology & Biotechnology. 36 (12): 1473–1482. doi:10.1007/s10295-009-0635-7. PMID 19756799. S2CID 32967249.
Singh JA, Hossain A, Kotb A, Wells G (September 2016). "Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis". BMC Medicine. 14 (1): 137. doi:10.1186/s12916-016-0673-8. PMC 5022202. PMID 27623861.
Singh JA, Hossain A, Kotb A, Wells GA (September 2016). "Comparative effectiveness of immunosuppressive drugs and corticosteroids for lupus nephritis: a systematic review and network meta-analysis". Systematic Reviews. 5 (1): 155. doi:10.1186/s13643-016-0328-z. PMC 5020478. PMID 27619512.
Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU (May 2006). "Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up". The American Journal of Gastroenterology. 101 (5): 1048–1056. doi:10.1111/j.1572-0241.2006.00524.x. PMID 16573777. S2CID 10233231.
Gordon M, Sinopoulou V, Akobeng AK, Pana M, Gasiea R, Moran GW (April 2022). "Tacrolimus (FK506) for induction of remission in corticosteroid-refractory ulcerative colitis". The Cochrane Database of Systematic Reviews. 2022 (4): CD007216. doi:10.1002/14651858.CD007216.pub2. PMC 8987360. PMID 35388476.

drugs.com

"Tacrolimus Use During Pregnancy". Drugs.com. 3 October 2019. Retrieved 29 April 2020.
Tacrolimus (Systemic) Monograph. Accessed 16 December 2021.

europa.eu

ema.europa.eu

"Advagraf EPAR". European Medicines Agency. 17 September 2018. Retrieved 16 July 2021.
"Protopic EPAR". European Medicines Agency. 17 September 2018. Retrieved 16 July 2021.
"Protopic EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 29 April 2020. This article incorporates text from this source, which is in the public domain.
"Advagraf EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 29 April 2020. This article incorporates text from this source, which is in the public domain.
"Modigraf EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 29 April 2020.

fda.gov

accessdata.fda.gov

"Prograf: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 30 April 2017. Retrieved 29 April 2020.
"Prograf: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 30 April 2017. Retrieved 29 April 2020.
"Tacrolimus: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 8 April 2019. Retrieved 29 April 2020.

handle.net

hdl.handle.net

World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.

medicinescomplete.com

Joint Formulary Committee. "British National Formulary (online)". London: BMJ Group and Pharmaceutical Press. Retrieved 24 September 2015.

medscape.com

McCauley J (19 May 2004). "Long-Term Graft Survival In Kidney Transplant Recipients". Slide Set Series on Analyses of Immunosuppressive Therapies. Medscape. Retrieved 6 June 2006.

mspca.org

"Tacrolimus, Ophthalmic" (PDF). Plumbs Veterinary Medication Guides. 2017. Archived from the original (PDF) on 18 December 2022. Retrieved 5 August 2022.

nih.gov

pubmed.ncbi.nlm.nih.gov

Berdoulay A, English RV, Nadelstein B (2005). "Effect of topical 0.02% tacrolimus aqueous suspension on tear production in dogs with keratoconjunctivitis sicca". Veterinary Ophthalmology. 8 (4): 225–232. doi:10.1111/j.1463-5224.2005.00390.x. PMID 16008701.
Baldo A, Cafiero M, Di Caterino P, Di Costanzo L (January 2009). "Tacrolimus ointment in the management of atopic dermatitis". Clinical, Cosmetic and Investigational Dermatology. 2: 1–7. doi:10.2147/ccid.s3378. PMC 3047924. PMID 21436963.
Haddad EM, McAlister VC, Renouf E, Malthaner R, Kjaer MS, Gluud LL (October 2006). McAlister V (ed.). "Cyclosporin versus tacrolimus for liver transplanted patients". The Cochrane Database of Systematic Reviews. 2006 (4): CD005161. doi:10.1002/14651858.CD005161.pub2. PMC 8865611. PMID 17054241.
O'Grady JG, Burroughs A, Hardy P, Elbourne D, Truesdale A (October 2002). "Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial". Lancet. 360 (9340): 1119–1125. doi:10.1016/S0140-6736(02)11196-2. PMID 12387959. S2CID 10417106.
Lee MN, Butani L (June 2007). "Improved pharmacokinetic monitoring of tacrolimus exposure after pediatric renal transplantation". Pediatric Transplantation. 11 (4): 388–393. doi:10.1111/j.1399-3046.2006.00618.x. PMID 17493218. S2CID 23530214.
Cury Martins J, Martins C, Aoki V, Gois AF, Ishii HA, da Silva EM (July 2015). "Topical tacrolimus for atopic dermatitis". The Cochrane Database of Systematic Reviews. 2015 (7): CD009864. doi:10.1002/14651858.CD009864.pub2. PMC 6461158. PMID 26132597.
Devasenapathy N, Chu A, Wong M, Srivastava A, Ceccacci R, Lin C, et al. (January 2023). "Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis". The Lancet. Child & Adolescent Health. 7 (1): 13–25. doi:10.1016/S2352-4642(22)00283-8. PMID 36370744. S2CID 253470127.
Silverberg NB, Lin P, Travis L, Farley-Li J, Mancini AJ, Wagner AM, et al. (November 2004). "Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases". Journal of the American Academy of Dermatology. 51 (5): 760–766. doi:10.1016/j.jaad.2004.05.036. PMID 15523355.
Yazu H, Fukagawa K, Shimizu E, Sato Y, Fujishima H (February 2021). "Long-term outcomes of 0.1% tacrolimus eye drops in eyes with severe allergic conjunctival diseases". Allergy, Asthma, and Clinical Immunology. 17 (1): 11. doi:10.1186/s13223-021-00513-w. PMC 7852099. PMID 33522964.
Fukatsu S, Fukudo M, Masuda S, Yano I, Katsura T, Ogura Y, et al. (April 2006). "Delayed effect of grapefruit juice on pharmacokinetics and pharmacodynamics of tacrolimus in a living-donor liver transplant recipient". Drug Metabolism and Pharmacokinetics. 21 (2): 122–125. doi:10.2133/dmpk.21.122. PMID 16702731.
Naesens M, Kuypers DR, Sarwal M (February 2009). "Calcineurin inhibitor nephrotoxicity". Clinical Journal of the American Society of Nephrology. 4 (2): 481–508. doi:10.2215/CJN.04800908. PMID 19218475.
Miwa Y, Isozaki T, Wakabayashi K, Odai T, Matsunawa M, Yajima N, et al. (2008). "Tacrolimus-induced lung injury in a rheumatoid arthritis patient with interstitial pneumonitis". Modern Rheumatology. 18 (2): 208–211. doi:10.1007/s10165-008-0034-3. PMID 18306979. S2CID 39537409.
O'Donnell MM, Williams JP, Weinrieb R, Denysenko L (2007). "Catatonic mutism after liver transplant rapidly reversed with lorazepam". General Hospital Psychiatry. 29 (3): 280–281. doi:10.1016/j.genhosppsych.2007.01.004. PMID 17484951.
Hanifin JM, Paller AS, Eichenfield L, Clark RA, Korman N, Weinstein G, et al. (August 2005). "Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis". Journal of the American Academy of Dermatology. 53 (2 Suppl 2): S186 – S194. doi:10.1016/j.jaad.2005.04.062. PMID 16021174.
Devasenapathy N, Chu A, Wong M, Srivastava A, Ceccacci R, Lin C, et al. (January 2023). "Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis". The Lancet. Child & Adolescent Health. 7 (1): 13–25. doi:10.1016/S2352-4642(22)00283-8. PMID 36370744. S2CID 253470127.
Cogliano VJ, Corsini E, Fournier A, Nelson HH, Sergi CM, Antunes AMM, et al. (29 November 2024). "Carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus". The Lancet Oncology. 26 (1): 15–16. doi:10.1016/S1470-2045(24)00685-5. PMID 39622256.{{cite journal}}: CS1 maint: multiple names: authors list (link)
Liu J, Farmer JD, Lane WS, Friedman J, Weissman I, Schreiber SL (August 1991). "Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes". Cell. 66 (4): 807–815. doi:10.1016/0092-8674(91)90124-H. PMID 1715244. S2CID 22094672.
Abou-Jaoude MM, Najm R, Shaheen J, Nawfal N, Abboud S, Alhabash M, et al. (September 2005). "Tacrolimus (FK506) versus cyclosporine microemulsion (neoral) as maintenance immunosuppression therapy in kidney transplant recipients". Transplantation Proceedings. 37 (7): 3025–3028. doi:10.1016/j.transproceed.2005.08.040. PMID 16213293.
Staatz CE, Tett SE (2004). "Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation". Clinical Pharmacokinetics. 43 (10): 623–653. doi:10.2165/00003088-200443100-00001. PMID 15244495. S2CID 33877550.
Staatz CE, Goodman LK, Tett SE (March 2010). "Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I". Clinical Pharmacokinetics. 49 (3): 141–175. doi:10.2165/11317350-000000000-00000. PMID 20170205. S2CID 28346861.
Staatz CE, Goodman LK, Tett SE (April 2010). "Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II". Clinical Pharmacokinetics. 49 (4): 207–221. doi:10.2165/11317550-000000000-00000. PMID 20214406. S2CID 27047235.
Barbarino JM, Staatz CE, Venkataramanan R, Klein TE, Altman RB (October 2013). "PharmGKB summary: cyclosporine and tacrolimus pathways". Pharmacogenetics and Genomics. 23 (10): 563–585. doi:10.1097/fpc.0b013e328364db84. PMC 4119065. PMID 23922006.
Benkali K, Prémaud A, Picard N, Rérolle JP, Toupance O, Hoizey G, et al. (1 January 2009). "Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients". Clinical Pharmacokinetics. 48 (12): 805–816. doi:10.2165/11318080-000000000-00000. PMID 19902988. S2CID 19900291.
Choi Y, Jiang F, An H, Park HJ, Choi JH, Lee H (January 2017). "A pharmacogenomic study on the pharmacokinetics of tacrolimus in healthy subjects using the DMETTM Plus platform". The Pharmacogenomics Journal. 17 (1): 105–106. doi:10.1038/tpj.2016.85. PMID 27958377.
Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M, et al. (September 1987). "FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics". The Journal of Antibiotics. 40 (9): 1249–1255. doi:10.7164/antibiotics.40.1249. PMID 2445721.
Pritchard DI (May 2005). "Sourcing a chemical succession for cyclosporin from parasites and human pathogens". Drug Discovery Today. 10 (10): 688–691. doi:10.1016/S1359-6446(05)03395-7. PMID 15896681. Supports source organism, but not team information
Ordóñez-Robles M, Santos-Beneit F, Martín JF (May 2018). "Unraveling Nutritional Regulation of Tacrolimus Biosynthesis in Streptomyces tsukubaensis through omic Approaches". Antibiotics. 7 (2): 39. doi:10.3390/antibiotics7020039. PMC 6022917. PMID 29724001.
Chen D, Zhang L, Pang B, Chen J, Xu Z, Abe I, et al. (May 2013). "FK506 maturation involves a cytochrome p450 protein-catalyzed four-electron C-9 oxidation in parallel with a C-31 O-methylation". Journal of Bacteriology. 195 (9): 1931–1939. doi:10.1128/JB.00033-13. PMC 3624582. PMID 23435975.
Mo S, Ban YH, Park JW, Yoo YJ, Yoon YJ (December 2009). "Enhanced FK506 production in Streptomyces clavuligerus CKD1119 by engineering the supply of methylmalonyl-CoA precursor". Journal of Industrial Microbiology & Biotechnology. 36 (12): 1473–1482. doi:10.1007/s10295-009-0635-7. PMID 19756799. S2CID 32967249.
Singh JA, Hossain A, Kotb A, Wells G (September 2016). "Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis". BMC Medicine. 14 (1): 137. doi:10.1186/s12916-016-0673-8. PMC 5022202. PMID 27623861.
Singh JA, Hossain A, Kotb A, Wells GA (September 2016). "Comparative effectiveness of immunosuppressive drugs and corticosteroids for lupus nephritis: a systematic review and network meta-analysis". Systematic Reviews. 5 (1): 155. doi:10.1186/s13643-016-0328-z. PMC 5020478. PMID 27619512.
Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU (May 2006). "Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up". The American Journal of Gastroenterology. 101 (5): 1048–1056. doi:10.1111/j.1572-0241.2006.00524.x. PMID 16573777. S2CID 10233231.
Gordon M, Sinopoulou V, Akobeng AK, Pana M, Gasiea R, Moran GW (April 2022). "Tacrolimus (FK506) for induction of remission in corticosteroid-refractory ulcerative colitis". The Cochrane Database of Systematic Reviews. 2022 (4): CD007216. doi:10.1002/14651858.CD007216.pub2. PMC 8987360. PMID 35388476.

ncbi.nlm.nih.gov

Baldo A, Cafiero M, Di Caterino P, Di Costanzo L (January 2009). "Tacrolimus ointment in the management of atopic dermatitis". Clinical, Cosmetic and Investigational Dermatology. 2: 1–7. doi:10.2147/ccid.s3378. PMC 3047924. PMID 21436963.
Haddad EM, McAlister VC, Renouf E, Malthaner R, Kjaer MS, Gluud LL (October 2006). McAlister V (ed.). "Cyclosporin versus tacrolimus for liver transplanted patients". The Cochrane Database of Systematic Reviews. 2006 (4): CD005161. doi:10.1002/14651858.CD005161.pub2. PMC 8865611. PMID 17054241.
Cury Martins J, Martins C, Aoki V, Gois AF, Ishii HA, da Silva EM (July 2015). "Topical tacrolimus for atopic dermatitis". The Cochrane Database of Systematic Reviews. 2015 (7): CD009864. doi:10.1002/14651858.CD009864.pub2. PMC 6461158. PMID 26132597.
Yazu H, Fukagawa K, Shimizu E, Sato Y, Fujishima H (February 2021). "Long-term outcomes of 0.1% tacrolimus eye drops in eyes with severe allergic conjunctival diseases". Allergy, Asthma, and Clinical Immunology. 17 (1): 11. doi:10.1186/s13223-021-00513-w. PMC 7852099. PMID 33522964.
Barbarino JM, Staatz CE, Venkataramanan R, Klein TE, Altman RB (October 2013). "PharmGKB summary: cyclosporine and tacrolimus pathways". Pharmacogenetics and Genomics. 23 (10): 563–585. doi:10.1097/fpc.0b013e328364db84. PMC 4119065. PMID 23922006.
Ordóñez-Robles M, Santos-Beneit F, Martín JF (May 2018). "Unraveling Nutritional Regulation of Tacrolimus Biosynthesis in Streptomyces tsukubaensis through omic Approaches". Antibiotics. 7 (2): 39. doi:10.3390/antibiotics7020039. PMC 6022917. PMID 29724001.
Chen D, Zhang L, Pang B, Chen J, Xu Z, Abe I, et al. (May 2013). "FK506 maturation involves a cytochrome p450 protein-catalyzed four-electron C-9 oxidation in parallel with a C-31 O-methylation". Journal of Bacteriology. 195 (9): 1931–1939. doi:10.1128/JB.00033-13. PMC 3624582. PMID 23435975.
Singh JA, Hossain A, Kotb A, Wells G (September 2016). "Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis". BMC Medicine. 14 (1): 137. doi:10.1186/s12916-016-0673-8. PMC 5022202. PMID 27623861.
Singh JA, Hossain A, Kotb A, Wells GA (September 2016). "Comparative effectiveness of immunosuppressive drugs and corticosteroids for lupus nephritis: a systematic review and network meta-analysis". Systematic Reviews. 5 (1): 155. doi:10.1186/s13643-016-0328-z. PMC 5020478. PMID 27619512.
Gordon M, Sinopoulou V, Akobeng AK, Pana M, Gasiea R, Moran GW (April 2022). "Tacrolimus (FK506) for induction of remission in corticosteroid-refractory ulcerative colitis". The Cochrane Database of Systematic Reviews. 2022 (4): CD007216. doi:10.1002/14651858.CD007216.pub2. PMC 8987360. PMID 35388476.

dailymed.nlm.nih.gov

"Prograf- tacrolimus capsule, gelatin coated Prograf- tacrolimus injection, solution Prograf- tacrolimus granule, for suspension". DailyMed. Retrieved 16 July 2021.

semanticscholar.org

api.semanticscholar.org

O'Grady JG, Burroughs A, Hardy P, Elbourne D, Truesdale A (October 2002). "Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial". Lancet. 360 (9340): 1119–1125. doi:10.1016/S0140-6736(02)11196-2. PMID 12387959. S2CID 10417106.
Lee MN, Butani L (June 2007). "Improved pharmacokinetic monitoring of tacrolimus exposure after pediatric renal transplantation". Pediatric Transplantation. 11 (4): 388–393. doi:10.1111/j.1399-3046.2006.00618.x. PMID 17493218. S2CID 23530214.
Devasenapathy N, Chu A, Wong M, Srivastava A, Ceccacci R, Lin C, et al. (January 2023). "Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis". The Lancet. Child & Adolescent Health. 7 (1): 13–25. doi:10.1016/S2352-4642(22)00283-8. PMID 36370744. S2CID 253470127.
Miwa Y, Isozaki T, Wakabayashi K, Odai T, Matsunawa M, Yajima N, et al. (2008). "Tacrolimus-induced lung injury in a rheumatoid arthritis patient with interstitial pneumonitis". Modern Rheumatology. 18 (2): 208–211. doi:10.1007/s10165-008-0034-3. PMID 18306979. S2CID 39537409.
Devasenapathy N, Chu A, Wong M, Srivastava A, Ceccacci R, Lin C, et al. (January 2023). "Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis". The Lancet. Child & Adolescent Health. 7 (1): 13–25. doi:10.1016/S2352-4642(22)00283-8. PMID 36370744. S2CID 253470127.
Liu J, Farmer JD, Lane WS, Friedman J, Weissman I, Schreiber SL (August 1991). "Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes". Cell. 66 (4): 807–815. doi:10.1016/0092-8674(91)90124-H. PMID 1715244. S2CID 22094672.
Staatz CE, Tett SE (2004). "Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation". Clinical Pharmacokinetics. 43 (10): 623–653. doi:10.2165/00003088-200443100-00001. PMID 15244495. S2CID 33877550.
Staatz CE, Goodman LK, Tett SE (March 2010). "Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I". Clinical Pharmacokinetics. 49 (3): 141–175. doi:10.2165/11317350-000000000-00000. PMID 20170205. S2CID 28346861.
Staatz CE, Goodman LK, Tett SE (April 2010). "Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II". Clinical Pharmacokinetics. 49 (4): 207–221. doi:10.2165/11317550-000000000-00000. PMID 20214406. S2CID 27047235.
Benkali K, Prémaud A, Picard N, Rérolle JP, Toupance O, Hoizey G, et al. (1 January 2009). "Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients". Clinical Pharmacokinetics. 48 (12): 805–816. doi:10.2165/11318080-000000000-00000. PMID 19902988. S2CID 19900291.
Mo S, Ban YH, Park JW, Yoo YJ, Yoon YJ (December 2009). "Enhanced FK506 production in Streptomyces clavuligerus CKD1119 by engineering the supply of methylmalonyl-CoA precursor". Journal of Industrial Microbiology & Biotechnology. 36 (12): 1473–1482. doi:10.1007/s10295-009-0635-7. PMID 19756799. S2CID 32967249.
Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU (May 2006). "Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up". The American Journal of Gastroenterology. 101 (5): 1048–1056. doi:10.1111/j.1572-0241.2006.00524.x. PMID 16573777. S2CID 10233231.

thelancet.com

Cogliano VJ, Corsini E, Fournier A, Nelson HH, Sergi CM, Antunes AMM, et al. (29 November 2024). "Carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus". The Lancet Oncology. 26 (1): 15–16. doi:10.1016/S1470-2045(24)00685-5. PMID 39622256.{{cite journal}}: CS1 maint: multiple names: authors list (link)

ucl.ac.uk

discovery.ucl.ac.uk

Bains RK. "Molecular diversity and population structure at the CYP3A5 gene in Africa" (PDF). University College London. Retrieved 13 June 2016.

web.archive.org

"The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
"Tacrolimus, Ophthalmic" (PDF). Plumbs Veterinary Medication Guides. 2017. Archived from the original (PDF) on 18 December 2022. Retrieved 5 August 2022.
Cox NH, Smith CH (December 2002). "Advice to dermatologists re topical tacrolimus" (PDF). Therapy Guidelines Committee. British Association of Dermatologists. Archived from the original (PDF) on 13 December 2013.
"Prograf: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 30 April 2017. Retrieved 29 April 2020.
"Prograf: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 30 April 2017. Retrieved 29 April 2020.
"Tacrolimus: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 8 April 2019. Retrieved 29 April 2020.

Tacrolimus (English Wikipedia)

bad.org.uk

canada.ca

cancer.org

clincalc.com

clinicaltrials.gov

doi.org

drugs.com

europa.eu

ema.europa.eu

fda.gov

accessdata.fda.gov

handle.net

hdl.handle.net

medicinescomplete.com

medscape.com

mspca.org

nih.gov

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

semanticscholar.org

api.semanticscholar.org

thelancet.com

ucl.ac.uk

discovery.ucl.ac.uk

web.archive.org

wedgewoodpetrx.com

who.int

monographs.iarc.who.int